Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
AVTX Avalo Therapeutics
5.460
+0.140+2.63%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
66.23% -265.4399 97.73% -81.5133 85.44% -1.22K 77.52% -612.8891
Receivable Turnover(T)
463.35% 24.2146 -22.63% 1.6188 80.69% 2.998 -20.87% 3.3349
Inventory Turnover(T)
86.30% 170.4211 759.44% 168.2791 346.44% 170.72 195.45% 72.4912
Fixed Assets Turnover(T)
107.16% 8.8711 -53.47% 1.8884 -1.60% 2.9502 -42.78% 2.5095
Total Asset Rate(T)
204.93% 0.2634 -18.82% 0.0784 18.44% 0.0974 -48.09% 0.0871
ROIC
-5.45% -109.394% -102.31% -268.154% 39.21% -139.115% 41.63% -145.117%
ROE
-36.17% -258.833% -355.68% -896.962% -62.44% -375.963% -37.48% -347.909%
ROA
22.57% -75.119% -36.65% -145.633% 6.28% -118.564% 7.37% -133.704%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -- -14.43% -158.675%
ROA 5 Year Average
-- -- -- -- -- -- -4.04% -70.010%
Average 5 Years ROIC
-- -- -- -- -- -- 5.39% -103.994%
Profitability Ratios TTM
Gross Margin
-1.77% 81.363% -95.63% 4.159% -30.07% 65.005% -24.23% 72.379%
Operating Margin
77.78% -267.918% -47.95% -1777.642% 27.16% -1187.389% -115.51% -1521.563%
Net Margin
74.61% -285.150% -68.33% -1857.722% 20.88% -1217.563% -78.43% -1535.309%
EBITDA Margin
69.83% -2.6547% -49.74% -17.556% 26.56% -11.6651% -119.73% -14.9087%
R & D Expense Ratio
-76.90% 210.920% 15.48% 1063.710% -39.14% 725.040% 130.65% 1108.470%
Sales Expense Ratio
-71.71% 10.630% 77.23% 61.480% 49.05% 70.830% 49.79% 52.350%
Administration Expense Rate
-59.54% 125.980% 103.31% 637.190% -1.66% 437.470% 55.55% 404.450%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- -- -- -- -- 523.144% -- 142.245%
Total Assets to Common Equity
-- -- -- -- 410.75% 975.863% 95.07% 347.518%
Debt to Asset Ratio
-- -- -- -- 49,247.44% 531.373% 8,215.35% 144.346%
Current Ratio
-73.51% 1.0717 -55.35% 0.9757 39.53% 2.44 82.06% 3.1097
Quick Ratio
-74.61% 1.006 -59.52% 0.8509 38.42% 2.2831 95.07% 2.9859
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- 11.43% -33.465%
Revenue CAGR(5Y)
-- -- -- -- -- -- -- 36.170%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
CEO: Dr. Garry A. Neil, M.D.
Market: NASDAQ
Listing Date: 11/13/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist